Symbols

ICU

SeaStar Medical·NASDAQ

--(--)

ICU fundamentals

ICU Q4 2025 Earnings

SeaStar Medical (ICU) released its earnings on Mar 25, 2026: revenue was 420.00K (YoY +526.87%), beat estimates; EPS was -0.8 (YoY +11.11%), beat estimates.

Revenue / YoY

420.00K

+526.87%

EPS / YoY

-0.8

+11.11%

Report date

Mar 25, 2026

ICU Earnings Call Summary for Q4,2025

Revenue Surge: 2025 net revenue up 723% to $1.1 million, with 90%+ gross margin.
Clinical Momentum: NEUTRALIZE-AKI trial 54% enrolled (181/339), targeting 2027 readout; pediatric AKI survival rate 76% vs. historical 30-40%.
Financial Strength: $24M capital raise in 2025, $12M cash, 26% expense reduction to $13.4M, net loss narrows to $1.2M.
Pipeline Expansion: SCD therapy for CRS-CRS trial underway; potential 2027 PMA submission for adult AKI under Breakthrough Designation.

Earnings

EPS

Revenue

Revenue & Expenses

ICU has released its 2025 Q4 earnings report, with revenue of 420.00K, reflecting a YoY change of 526.87%, and net profit of -2.90M, showing a YoY change of 34.28%. The Sankey diagram below clearly presents ICU's revenue sources and cost distribution.

Key Indicators

SeaStar Medical (ICU) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

SeaStar Medical (ICU)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

SeaStar Medical (ICU)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

SeaStar Medical (ICU)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown